Critical appraisal of loteprednol ointment, gel, and suspension in the treatment of postoperative inflammation and pain following ocular and corneal transplant surgery

Figures & data

Figure 1 Loteprednol etabonate 0.5% ointment, Bausch and Lomb Incorporated, Rochester, NY, USA.

Figure 2 Loteprednol etabonate molecular structure: loteprednol etabonate is synthesized through structural modifications of a prednisolone-related compound.

Notes: Chemical name: chloromethyl 17α-[(ethoxycarbonyl)oxy]-11β-hydroxy-3-oxoandrosta-1,4-diene-17β-carboxylate. Active compound: loteprednol etabonate 5 mg (0.5%). Inactive compounds: mineral oil and white petrolatum.

Figure 3 Change in intraocular pressure after treatment with Lotemax® ointment or vehicle.

Notes: Values shown are the mean ± the standard error of the mean. Lotemax 0.5%, Bausch and Lomb Incorporated, Rochester, NY, USA. Copyright © 2011. Reproduced from Dove Medical Press. Comstock TL, Paterno MR, Singh A, Erb T, Davis E. Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery. Clin Ophthalmol. 2011;5:177–186.⁴²
Abbreviation: Lotemax, Ioteprednol etabonate.

Table 1 Published clinical studies on Lotemax® and penetrating keratoplasty

Investigators	Year	Journal	Topic	Design
Randleman and Stulting^Citation22	2006	Cornea	Corneal graft and steroid	Survey
Erdmus et al^Citation7	2009	Cornea	IOP and steroid	Retrospective chart review
Holland et al^Citation40	2009	Cornea	IOP and steroid	Retrospective chart review

Note: Lotemax, Bausch and Lomb Incorporated, Rochester, NY, USA.

Abbreviation: IOP, intraocular pressure.

Table 2 Comparative studies on efficacy and safety of Lotemax® 0.5% in resolution of postoperative inflammation

Investigators	Journal	Year	Total patients	Follow-up	Comparative drug
Lane and Holland^Citation31	J Cataract Refract Surg	2013	88	21 days	PF 1.0%
Stewart et al^Citation32	J Cataract Refract Surg	1998	227	14 days	Placebo
Fong et al^Citation34	Clin Ophthalmol	2012	407	14 days	Vehicle
Oner et al^Citation36	Jpn J Ophthalmol	2012	60	28 days	PF 1.0% and FML 0.1%
Holzer et al^Citation37	J Cataract Refract Surg	2002	60	30 days	Acular 0.5%
Rajpal et al^Citation41	J Cataract Refract Surg	2013	406	14 days	Vehicle
Comstock et al^Citation42	Clin Ophthalmol	2011	805	8 days	Vehicle

Note: Lotemax, Bausch and Lomb Incorporated, Rochester, NY, USA.

Abbreviations: PF, prednisolone acetate; FML, fluorometholone.

ComstockTLPaternoMRSinghAErbTDavisESafety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgeryClin Ophthalmol2011517718621383946

 PubMedGoogle Scholar

RandlemanBJStultingRDPrevention and treatment of corneal graft rejection: current practice patternsCornea20062528629016633028

 PubMed Web of Science ®Google Scholar

ErdurmusMCohenEJYildizEHSteroid-induced intraocular pressure elevation or glaucoma after penetrating keratoplasty in patients with keratoconus or Fuchs dystrophyCornea20092875976419574912

 PubMed Web of Science ®Google Scholar

HollandEJDjalilianARSandersonJPAttenuation of ocular hypertension with the use of topical loteprednol etabonate 0.5% in steroid responders after corneal transplantationCornea2009281139114319770719

 PubMed Web of Science ®Google Scholar

LaneSSHollandEJLoteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgeryJ Cataract Refract Surg20133916817323232255

 PubMed Web of Science ®Google Scholar

StewartRHorwitzBHowesJNovackGDHartKDouble-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group 1J Cataract Refract Surg199824148014899818338

 PubMed Web of Science ®Google Scholar

FongRLeitritzMSiou-MermetRErbTLoteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trialClin Ophthalmol201261113112422888209

 PubMedGoogle Scholar

OnerVTürkcüFMTaşMAlakuşMFIşcanYTopical loteprednol etabonate 0.5% for treatment of vernal keratoconjunctivitis: efficacy and safetyJpn J Ophthalmol20125631231822622345

 PubMed Web of Science ®Google Scholar

HolzerMPSolomonKDSandovalHPVromanDTComparison of ketorolac tromethamine 0.5% and loteprednol etabonate 0.5% for inflammation after phacoemulsification: prospective randomized double-masked studyJ Cataract Refract Surg200228939911777716

 PubMed Web of Science ®Google Scholar

RajpalRKRoelLSiou-MermetRErbTEfficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgeryJ Cataract Refract Surg20133915816723218817

 PubMed Web of Science ®Google Scholar